Earnings Per Share (EPS) of $0.02, surpassing estimates.Revenue reached $161.13 million, exceeding expectations.Financial Health indicated by a P/E ratio of approximately 22.46 and a low debt-to-equity ratio of 0.15.Trex Company, Inc. (NYSE:TREX) is a leading manufacturer of wood-alternative decking and railing products. As the largest in its industry, Trex has established a strong market presence. The company competes with other manufacturers in the building materials sector, focusing on sustainable and in ...

Financial Performance - Addus HomeCare reported a 25.6% increase in net service revenues, reaching $373.1 million for the fourth quarter of 2025 [2][6] - The company's net income for the fourth quarter was $29.8 million, or $1.61 per diluted share, with adjusted net income per diluted share increasing by 28.3% year-over-year to $1.77 [3][6] - Adjusted EBITDA grew by 33.3% year-over-year, amounting to $50.3 million, indicating strong financial health and cash flow generation [4][6] Stock Performance - Despite strong financial results, Addus HomeCare's stock price has decreased by 10.57%, currently trading at $105.20 [4][6] - The stock has fluctuated between $101 and $113 today, with a 52-week high of $124.44 and a low of $88.96 [5] - The company's market capitalization is approximately $1.94 billion, with a trading volume of 679,173 shares, reflecting strong investor interest [5]

For the quarter ended December 2025, Axsome Therapeutics (AXSM) reported revenue of $196 million, up 65% over the same period last year. EPS came in at -$0.71, compared to -$0.96 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $193.01 million, representing a surprise of +1.55%. The company delivered an EPS surprise of -1%, with the consensus EPS estimate being -$0.70.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Appian (APPN) reported $202.87 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 21.7%. EPS of $0.15 for the same period compares to $0 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $189.1 million, representing a surprise of +7.28%. The company delivered an EPS surprise of +59.57%, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Enpro (NPO) reported $295.4 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 14.3%. EPS of $1.99 for the same period compares to $1.57 a year ago.The reported revenue represents a surprise of +5.31% over the Zacks Consensus Estimate of $280.5 million. With the consensus EPS estimate being $1.91, the EPS surprise was +4.01%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

ReposiTrak reported an EPS of $0.08, slightly below the estimated $0.09 but exceeded revenue expectations with $5.9 million.The company saw a 7% increase in total revenue, reaching $5.9 million up from $5.5 million the previous year.TRAK's financial health is solid with a P/E ratio of approximately 25.36, a low debt-to-equity ratio of 0.008, and a current ratio of approximately 5.45.ReposiTrak, Inc. (NYSE:TRAK) is a leading player in the food traceability and regulatory compliance sector. The company is kno ...

Core Insights - Glaukos reported revenue of $143.12 million for Q4 2025, a year-over-year increase of 35.7% and slightly above the Zacks Consensus Estimate of $142.93 million, resulting in a surprise of +0.13% [1] - The company reported an EPS of -$0.28, which is an improvement from -$0.40 a year ago, but fell short of the consensus estimate of -$0.22, leading to an EPS surprise of -26.47% [1] Revenue Performance - International Glaucoma revenues reached $32.78 million, exceeding the average estimate of $31.67 million by six analysts, representing a year-over-year increase of +17.6% [4] - United States Glaucoma revenues were reported at $86.4 million, surpassing the average estimate of $81.11 million, with a significant year-over-year change of +53.5% [4] - Net Sales for Corneal Health amounted to $24 million, exceeding the average estimate of $21.06 million, reflecting a year-over-year increase of +12.4% [4] - Net Sales for Glaucoma totaled $119.2 million, above the average estimate of $112.79 million, indicating a year-over-year change of +41.7% [4] Stock Performance - Over the past month, Glaukos shares have returned -9%, compared to a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Zillow Group reported revenue of $654 million for the quarter ended December 2025, marking an 18.1% increase year-over-year, with EPS at $0.39 compared to $0.27 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $649.76 million by 0.65%, while the EPS fell short of the consensus estimate of $0.42 by 6.25% [1] Financial Performance Metrics - Average Monthly Unique Users for Zillow's mobile applications and websites reached 221 million, surpassing the estimated 215.1 million [4] - Total visits to mobile applications and websites were 2.1 billion, slightly above the average estimate of 2.11 billion [4] - Residential revenue was reported at $418 million, exceeding the average estimate of $415.98 million, reflecting an 8% year-over-year increase [4] - Revenue from other segments was $11 million, compared to the average estimate of $11.62 million, showing a 10% year-over-year increase [4] - Mortgage revenue reached $57 million, surpassing the average estimate of $50.89 million, with a significant year-over-year increase of 39% [4] - Rental revenue was reported at $168 million, slightly below the estimated $172.17 million, but still reflecting a substantial year-over-year increase of 44.8% [4] Stock Performance - Zillow's shares have declined by 19.7% over the past month, contrasting with the Zacks S&P 500 composite, which remained unchanged [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Cognizant Technology Solutions Corporation (CTSH) is a leading provider of IT, consulting, and business process services, competing with major players like Accenture and Infosys [1] Stock Performance - Over the past month, CTSH has shown a modest gain of 0.53%, indicating steady growth and investor confidence [2] - In the last 10 days, the stock experienced a decline of 3.16%, presenting a potential buying opportunity as it has touched a local minimum, suggesting a possible rebound [2][6] Growth Potential - CTSH's growth potential is forecasted at an impressive 15.09%, driven by market trends, company performance, and industry outlook, making it attractive for investors seeking future appreciation [3] Financial Health - The company has a strong Piotroski Score of 8, indicating robust financial health and effective management, providing reassurance to investors about its stability [4][6] Analyst Target Price - Analysts have set a target price for CTSH at $94.44, reflecting significant upside potential from current levels and confidence in the company's ability to achieve growth objectives [5]

The start of a new year is a natural time to reflect on goals, and financial health should be part of that conversation. Here are eight smart resolutions to consider as you align your finances with your future retirement goals in 2026 and beyond.Read more: https://t.co/KmfSbyER6A ...